JX09

JX09 (formerly known as PB6440, SE6440, or VT6440) is a highly selective oral small molecule inhibitor of aldosterone synthase (CYP11B2), currently in Phase 1 clinical trials for the treatment of hypertension and resistant hypertension. Developed initially by Selenity Therapeutics and further advanced by Corxel Pharmaceuticals (formerly Ji Xing Pharmaceuticals), JX09 is designed to lower aldosterone levels with minimal impact on cortisol synthesis due to its high selectivity (>300-fold for CYP11B2 over CYP11B1). This mechanism directly targets the synthesis of aldosterone—a key mediator in hypertension, heart failure, and chronic kidney disease—offering a novel therapeutic approach where no approved aldosterone synthase inhibitors currently exist. Preclinical data indicate strong potency and safety potential compared to other agents in this class[1][2][3][4][5].

Other names

PB6440PB-6440PB 6440